Protalix BioTherapeutics, Inc., a New Jersey-based biopharmaceutical company, is making waves in the industry with the development, production, and commercialization of recombinant therapeutic proteins. Using their proprietary ProCellEx plant cell-based protein expression system, Protalix is expanding their reach both nationally and internationally, with operations in countries such as Australia, Canada, Israel, Brazil, Russia, and Turkey. The company's flagship product, Elelyso, offers hope to those suffering from the rare genetic disorder, Gaucher disease. But their efforts don't stop there, as they are currently developing PRX-102, a protein candidate that could transform the treatment of Fabry disease. Protalix is also taking aim at gout with PRX-115, a plant cell-expressed recombinant PEGylated Uricase, and NETs-related diseases with PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate. With partnerships and agreements with heavyweights such as Pfizer, Fundação Oswaldo Cruz (Fiocruz), and Chiesi Farmaceutici S.p.A., Protalix is on track to change the face of biopharmaceuticals as we know it.
Protalix BioTherapeutics, Inc.'s ticker is PLX
The company's shares trade on the AMEX stock exchange
They are based in Karmiel, Israel
There are 201-500 employees working at Protalix BioTherapeutics, Inc.
It is http://www.protalix.com/
Protalix BioTherapeutics, Inc. is in the Healthcare sector
Protalix BioTherapeutics, Inc. is in the Biotechnology industry
The following five companies are Protalix BioTherapeutics, Inc.'s industry peers: